Related Experiment Video

Updated: Jun 29, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers

Hiroshi Maruta1, Hong He2

  • 1PAK Research Center, Melbourne, Australia.

Drug Discoveries & Therapeutics
|April 3, 2024
PubMed

Insights

PAK1 (RAC/CDC42-activating kinase 1) and TOR (Target of Rapamycin) kinases have opposing roles in immunity. PAK1 blockers show promise for cancer therapy and longevity by inhibiting melanogenesis, unlike TOR blockers.

Area of Science:

  • Biochemistry
  • Oncology
  • Immunology
  • Aging Research

Background:

  • PAK1 (RAC/CDC42-activating kinase 1) and TOR (Target of Rapamycin) are key kinases implicated in cancer and aging.
  • These kinases play contrasting roles in immune system regulation: PAK1 suppresses immunity, while TOR is essential for its function.

Purpose of the Study:

  • To investigate the differential roles of PAK1 and TOR in immune function and cancer.
  • To identify effective therapeutic strategies targeting these kinases for cancer therapy and longevity.
  • To explore melanogenesis as a potential indicator for distinguishing PAK1-blockers from TOR-blockers.

Main Methods:

  • Screening of PAK1-blockers as melanogenesis inhibitors.
  • Utilizing rapamycin (TOR-inhibitor) and TORin-1 (novel TOR-inhibitor) in cell culture models.
  • Assessing the impact of these inhibitors on immune system function and melanogenesis.

Main Results:

  • PAK1 inhibition was found to inhibit melanogenesis and potentially promote longevity.
  • Rapamycin, a TOR-inhibitor, promotes melanogenesis, suggesting TOR suppresses this process.
  • TORin-1, while classified as a TOR-inhibitor, exhibited PAK1-blocker-like effects by not suppressing the immune system and blocking melanogenesis in vitro.

Conclusions:

  • PAK1-blockers are likely more effective for cancer therapy than TOR-blockers due to their opposing immune roles.
  • Melanogenesis in cell culture may serve as a reliable method to differentiate between PAK1-blockers and TOR-blockers in vivo.
  • TORin-1's observed effects suggest it may function as a PAK1-blocker in vivo, offering a novel therapeutic avenue.
Keywords:
GleevecPAK1TORTORin-1immune systemmelanogenesisnilotinibrapamycin

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

364

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
153
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K